Antitumor activity of a monoclonal antibody directed against gastrin- releasing peptide in patients with small cell lung cancer

Chest

Volumn 112, Issue 1, 1997, Pages 256-261

  Kelley, Michael J ^a,c   Linnoila, R Ilona ^a   Avis, Ingalill L ^a   Georgiadis, Mark S ^b   Cuttitta, Frank ^a   Mulshine, James L ^a   Johnson, Bruce E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Navy Medical Oncology   (United States)

Author keywords

Autocrine growth factor; HAMA; Lung neoplasm; Monoclonal antibody; Phase 2 clinical total therapy

Indexed keywords

GASTRIN RELEASING PEPTIDE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; FEMALE; GASTRIN RELEASE; HUMAN; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL;

EID: 0030759810     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.1.256     Document Type: Article

References (24)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. Ca Cancer J Clin 1996; 46:5-27
2. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327:1434-41
3. Mendelsohn J, Lippman ME. Principles of molecular cell biology of cancer: growth factor. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: J B Lippincott, 1993; 114-33
4. Johnson BE, Kelley MJ. Biology of small cell lung cancer. Lung Cancer 1995; 12:S5-S16
5. Sporn MB, Todaro GJ. Antocrine secretion and malignant transformation of cells. N Engl J Med 1980; 303:878-80
6. Sporn MB, Roberts AB. Antocrine secretion - 10 years later. Ann Intern Med 1992; 117:408-14
7. Cuttitta F, Carney DC, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316:823-26
8. Mulshine J, Avis I, Carrasquillo J, et al. Phase I study of an anti gastrin releasing peptide monoclonal antibody in patients with lung cancer [abstract]. Proc Am Soc Clin Oncol 1990; 9:230
9. Mulshine JL, Shuke N, Daghighian F, et al. The correct dose: pharmacologically guided end point for anti-growth factor therapy. Cancer Res 1992; 52:2743S-46S
10. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10
11. Johnson BE, Bridges JD, Sobczeck M, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14:806-13
12. Kelley MJ, Holden D, Le PT, et al. Feasibility of use of plasma and urine levels of gastrin releasing peptide and insulin-like growth factor I as potential predictors for risk of second lung cancer development among patients with stage I or II non-small cell lung cancer [abstract]. Lung Cancer 1994; 11(suppl 1):58
13. Avis IL, Kovacs TOG, Kasprzyk PG, et al. Preclinical evaluation of an anti-antocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer. J Natl Cancer Inst 1991; 83:1470-76
14. Mulshine JL, Avis I, Treston AM, et al. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann NY Acad Sci 1988; 547:360-72
15. Cuttitta F, Fedorko J, Gu JA, et al. Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man. J Clin Endocrinol Metab 1988; 67:576-83
16. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer: the LCSG experience. Chest 1994; 106:367S-71S
17. Ebina M, Steinberg SM, Mulshine JL, et al. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994; 54:2496-2503
18. Sunday ME, Choi N, Spindel ER, et al. Gastrin-releasing peptide gene expression in small cell and large cell undifferentiated lung carcinomas. Hum Pathol 1991; 22:1030-39
19. Linnoila RI, Mulshine JL, Steinberg SM, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol 1988; 90:641-52
20. Corjay MH, Dobrzanski DJ, Way JM, et al. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem 1877; 266:18771-79
21. Moody TW, Murphy A, Mahmoud S, et al. Bombesin-peptides elevate cytosolic calcium in small cell lung cancer cells. Biochem Biophy Res Commun 1987; 147:189-95
22. Yang HK, Kelley MJ, Battey JF, et al. Correlation of gastrin-releasing peptide, gastrin-releasing peptide receptor and neuromedin B receptor mRNA expression in small cell lung cancer cell lines with in vitro response to antibombesin monoclonal antibody (2A11) [abstract]. Proc Annu Meet Am Assoc Cancer Res 1993; 34:343
23. Yoneda K, Boucher LD. Bronchial epithelial changes associated with small cell carcinoma of the lung. Hum Pathol 1993; 24:1180-83
24. Chute JP, Venzon DJ, Hankins L, et al. Twenty years of clinical research on patients with small cell lung cancer shows modest prolongation of survival in recently treated limited stage patients [abstract]. Proc Am Soc Clin Oncol 1995; 14:354